公开(公告)号：US20240307266A1

公开(公告)日：2024-09-19

申请号：US18606872

申请日：2024-03-15

Applicant: Heron Therapeutics, Inc.

Inventor： Lee Ann Lynn Girotti ,  Thomas B. Ottoboni

IPC: A61J1/20

CPC classification number: A61J1/2096 ,  A61J1/201 ,  A61J1/2055

Abstract: A vial access needle device is described. The device comprises a base with a base plate and with a base wall that extending proximally from the base plate. The base wall is configured to receive a portion of a base of a vial. The device also comprises a cap having a proximal closed end and configured to removably attach to the base, the proximal closed end having a proximal side and a distal side. A cap wall extends distally from the proximal closed end and is configured to receive a neck and a portion of the vial. The cap is configured to be removably attached to the base plate and to form an air-tight seal with the base.

公开(公告)号：US20210205458A1

公开(公告)日：2021-07-08

申请号：US17209078

申请日：2021-03-22

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Lee Ann Lynn Girotti

IPC: A61K47/34 ,  A61K31/445 ,  A61K47/12 ,  A61K9/00 ,  A61K31/245 ,  A61K31/47 ,  A61K31/167 ,  A61K31/00

Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.

公开(公告)号：US10980886B2

公开(公告)日：2021-04-20

申请号：US14691491

申请日：2015-04-20

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Lee Ann Lynn Girotti

IPC: A61K47/34 ,  A61K9/00 ,  A61K31/445 ,  A61K47/12 ,  A61K31/245 ,  A61K31/47 ,  A61K31/167 ,  A61K31/00

Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.

公开(公告)号：US20190000762A1

公开(公告)日：2019-01-03

申请号：US15965638

申请日：2018-04-27

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K9/107 ,  A61K31/496 ,  A61K31/43 ,  A61K47/10 ,  A61K47/44 ,  A61K47/24 ,  A61K9/00 ,  A61K31/435 ,  A61K31/5377 ,  A61K31/573

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US09974794B2

公开(公告)日：2018-05-22

申请号：US15705208

申请日：2017-09-14

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K31/5377 ,  A61K47/44 ,  A61K47/26 ,  A61K47/24 ,  A61K9/00 ,  A61K31/573 ,  A61K9/107 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/107 ,  A61K31/573 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44

Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US09974793B2

公开(公告)日：2018-05-22

申请号：US15705201

申请日：2017-09-14

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K31/5377 ,  A61K47/44 ,  A61K47/26 ,  A61K47/24 ,  A61K9/107 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K9/00 ,  A61K31/573

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/107 ,  A61K31/573 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44

Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US09974742B2

公开(公告)日：2018-05-22

申请号：US15012532

申请日：2016-02-01

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K9/107 ,  A61K9/00 ,  A61K47/24 ,  A61K31/661 ,  A61K47/12 ,  A61K47/44 ,  A61K47/10 ,  A61K31/435 ,  A61K31/496 ,  A61K31/43 ,  A61K31/5377 ,  A61K31/573

CPC classification number: A61K9/1075 ,  A61K9/0019 ,  A61K31/43 ,  A61K31/435 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/573 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  A61K2300/00

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US20180000829A1

公开(公告)日：2018-01-04

申请号：US15705208

申请日：2017-09-14

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K31/5377 ,  A61K47/26 ,  A61K47/24 ,  A61K47/12 ,  A61K9/00 ,  A61K47/10 ,  A61K31/573 ,  A61K9/107 ,  A61K47/44 ,  A61K47/18

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/107 ,  A61K31/573 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44

Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US20170216205A1

公开(公告)日：2017-08-03

申请号：US15012532

申请日：2016-02-01

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K9/107 ,  A61K47/24 ,  A61K31/661 ,  A61K31/496 ,  A61K47/44 ,  A61K47/10 ,  A61K31/435 ,  A61K9/00 ,  A61K47/12

CPC classification number: A61K9/1075 ,  A61K9/0019 ,  A61K31/43 ,  A61K31/435 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/573 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  A61K2300/00

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US20170112847A1

公开(公告)日：2017-04-27

申请号：US15398928

申请日：2017-01-05

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K31/5377 ,  A61K47/24 ,  A61K47/12 ,  A61K9/107 ,  A61K47/44 ,  A61K47/10 ,  A61K9/00 ,  A61K31/573 ,  A61K47/18

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/107 ,  A61K31/573 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44

Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.